The safety and efficacy of miltefosine in the long-term treatment of post-kala-azar dermal leishmaniasis in South Asia - A review and meta-analysis.

• Published in: PLOS Neglected Tropical Diseases
• Main Authors: Joyce Pijpers, Margriet L den Boer, Dirk R Essink, Koert Ritmeijer
• Format: Article in Journal/Newspaper
• Language: English
• Published: Public Library of Science (PLoS) 2019
• Subjects: Arctic medicine. Tropical medicine; RC955-962; Public aspects of medicine; RA1-1270; Arctic; Azar
• Online Access: https://doi.org/10.1371/journal.pntd.0007173; https://doaj.org/article/996cc8076cdf4faba2db771661342223

BACKGROUND:Miltefosine (MF) is the only oral drug available for treatment of visceral leishmaniasis (VL) and post-kala-azar dermal leishmaniasis (PKDL). Although the drug is effective and well tolerated in treatment of VL, the efficacy and safety of MF for longer treatment durations (>28 days) in...